List of Excipients in Branded Drug INFED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	INFED	iron dextran	0023-6082	SODIUM HYDROXIDE
Henry Schein Inc	INFED	iron dextran	0404-9879	SODIUM HYDROXIDE
Actavis Pharma Inc	INFED	iron dextran	52544-931	SODIUM HYDROXIDE

INFED Excipient Strategy and Commercial Opportunities in Iron Dextran Injection

Last updated: August 28, 2026

INFeD is an iron dextran parenteral product containing 50 mg/mL elemental iron for intravenous or intramuscular administration. Its commercial opportunity is driven less by conventional excipient innovation than by injectable-product execution: low particulate burden, controlled pH, container compatibility, administration safety, and reliable supply. The main strategic constraint is that dextran is part of the iron complex and materially affects the product’s clinical and regulatory identity. A reformulator therefore cannot freely substitute the dextran component without creating a new iron-carbohydrate complex.

What is INFeD and what excipients does it contain?

INFeD is iron dextran injection, USP. Each milliliter contains 50 mg of elemental iron in an iron-dextran complex. The product is supplied as a sterile aqueous injection and is administered by intravenous infusion or injection or by deep intramuscular injection under labeled conditions. The FDA label identifies water for injection as the vehicle and permits hydrochloric acid and/or sodium hydroxide for pH adjustment.[1]

Product attribute	INFeD profile
Active pharmaceutical component	Iron-dextran complex
Elemental iron concentration	50 mg/mL
Dosage form	Sterile injectable solution
Routes	Intravenous and intramuscular
Primary vehicle	Water for injection
pH control	Hydrochloric acid and/or sodium hydroxide
Preservative strategy	Single-dose presentation; no preservative-dependent multidose strategy identified in the FDA label
Primary packaging	Glass ampule presentations identified in labeling
Therapeutic category	Parenteral iron replacement
Regulatory status	FDA-approved prescription drug

The excipient list is unusually short because the formulation relies on the iron-dextran complex for the product’s colloidal and physicochemical behavior. The commercial and technical importance of dextran is greater than that of the nominal inactive ingredients.

Is dextran an excipient or the active component?

Dextran is chemically integrated into the iron-carbohydrate complex. In regulatory and pharmaceutical terms, it should not be treated like a conventional inactive excipient such as polysorbate, citrate, or sodium chloride. The dextran molecular-weight distribution, iron loading, particle size, free-iron content, and complex stability can affect pharmacology, tolerability, immunogenicity, and bioequivalence.

This distinction limits reformulation freedom. Replacing the dextran with another polysaccharide would generally produce a different iron complex rather than an improved version of the same drug.

What is the optimal excipient strategy for an INFeD competitor?

The strongest strategy is a minimal, preservative-free aqueous formulation that matches the reference product’s critical quality attributes while improving manufacturability and packaging.

Core formulation strategy

A competitive product should prioritize:

1. Water for injection with controlled ionic and organic impurity levels.
2. Tight pH control using hydrochloric acid and sodium hydroxide.
3. No unnecessary buffer system unless stability data require one.
4. Low extractables and leachables from the container-closure system.
5. Control of visible and subvisible particles.
6. Consistent iron-dextran complex size and iron release.
7. Compatibility with intravenous administration equipment.
8. Single-dose packaging to avoid antimicrobial-preservative complications.

A buffer may improve pH robustness, but it can also alter colloidal stability, osmolality, iron release, and compatibility with infusion fluids. Phosphate, citrate, acetate, and other multivalent or coordinating species require particular caution because they can interact with iron or affect complex integrity.

Why a minimal excipient system is commercially attractive

A short excipient list reduces several development risks:

• Fewer raw-material qualification requirements.
• Lower risk of excipient-mediated hypersensitivity.
• Simpler comparability against the reference product.
• Reduced analytical burden under an abbreviated application.
• Lower risk of precipitation or incompatibility during dilution.
• Easier global registration where injectable excipient precedents differ by jurisdiction.

The principal development effort should be placed in characterization of the iron-dextran complex, not in adding functional excipients.

What formulation patents protect INFeD?

INFeD is an established iron-dextran injectable with no obvious commercial value in a new excipient patent covering the basic aqueous composition alone. The principal intellectual-property opportunity would more likely involve a differentiated delivery system, complex-engineering process, or stability-enhancing presentation.

Potential patentable areas include:

Potential claim area	Commercial value	Key vulnerability
New iron-dextran particle-size distribution	High if clinically meaningful	May be viewed as an inherent property or require extensive equivalence work
Reduced free iron	High	Requires validated analytical methods and clinical relevance
Reduced immunogenicity	Very high	Requires robust mechanistic and clinical evidence
Ready-to-administer diluted infusion	Medium	May face obviousness and stability challenges
Prefilled syringe or autoinjector	Medium	Device and viscosity constraints
Improved ampule or vial closure	Low to medium	Narrow protection and design-around risk
Extended room-temperature stability	Medium	Must be supported by real-time data
Novel buffer or stabilizer system	Low to medium	May undermine reference-product comparability
Manufacturing process for complex formation	High	Process claims can be difficult to enforce without access to manufacturing evidence
Low-volume high-concentration formulation	High	Concentration may affect viscosity, safety, and complex stability

A patent strategy based only on adding a conventional buffer, chelator, surfactant, or tonicity agent would likely have limited durability. Patent value increases when the formulation change produces a measurable clinical, stability, administration, or manufacturing advantage.

When does INFeD lose exclusivity?

INFeD is an old small-molecule-associated parenteral product, and its original composition and use patents are unlikely to provide meaningful remaining exclusivity. The relevant commercial barriers are regulatory approval, complex-product equivalence, manufacturing controls, supply reliability, and physician familiarity.

The FDA Orange Book is the controlling source for current listed patents, exclusivity, therapeutic-equivalence codes, and approved products.[2] For an established product such as INFeD, an entrant should distinguish among:

• Patent expiry.
• Regulatory exclusivity expiry.
• Absence or presence of listed patents.
• Approval of an equivalent product.
• Commercial availability of that approved product.
• Hospital formulary adoption.

A nominally unprotected product can still maintain commercial share if the reference manufacturer controls supply, has favorable contracting, or benefits from clinician familiarity.

What patent litigation affects INFeD?

There is no widely recognized modern patent litigation campaign comparable to litigation surrounding major biologics or high-revenue specialty drugs. The practical litigation risk is more likely to arise from:

• Manufacturing-process patents.
• Complex iron-carbohydrate characterization.
• Device or packaging patents.
• Trade-secret disputes involving complex formation.
• Product liability claims related to hypersensitivity or administration errors.
• False patent-certification or labeling disputes if a current Orange Book listing exists.

A Paragraph IV strategy would be relevant only if a current listed patent blocks approval. For an old injectable product, the more likely pathway is an ANDA relying on the reference product’s safety and efficacy, subject to FDA requirements for pharmaceutical equivalence and product-specific characterization.

How difficult is an ANDA for generic iron dextran?

Generic iron dextran is more difficult than a conventional aqueous small-molecule injection because the active material is a coordination or colloidal complex rather than a simple molecular entity.

The applicant must address:

• Identity and composition of the iron-dextran complex.
• Iron content and concentration.
• Dextran molecular-weight distribution.
• Iron-to-dextran ratio.
• Particle or aggregate-size distribution.
• Free iron and labile iron.
• pH and osmolality.
• Viscosity.
• Sterility and endotoxin limits.
• Visible and subvisible particulate matter.
• Container-closure integrity.
• Stability under labeled storage conditions.
• Comparative release and physicochemical behavior.

FDA’s regulatory approach to complex iron products has required increasingly detailed analytical characterization. The product may not be adequately described by standard compendial assays alone. A sponsor should expect scrutiny of orthogonal methods, including chromatography, light scattering, spectroscopy, microscopy, iron-release testing, and molecular-weight analysis.[3]

Is a preservative-containing INFeD formulation attractive?

Generally, no. A preservative-containing formulation could support a multidose vial, but it would introduce:

• New tolerability and hypersensitivity considerations.
• Additional extractables and leachables analysis.
• Container-closure interaction risk.
• Potential incompatibility with intravenous use.
• A more difficult reference-product comparison.
• New labeling and in-use stability requirements.

The better commercial route is a single-dose vial or ampule with efficient dose presentation and minimal residual volume.

What commercial opportunities exist for INFeD excipient innovation?

Ready-to-use infusion presentations

Hospitals face preparation, dilution, and medication-error costs. A ready-to-use or pharmacy-ready presentation could create value if it maintains iron-complex stability and meets container-closure requirements.

Potential formats include:

• Pre-diluted infusion bags.
• Small-volume intravenous containers.
• Pharmacy-compounded dilution kits.
• Unit-dose vials with standardized administration instructions.

The commercial advantage would come from workflow reduction rather than a new therapeutic effect.

Improved container-closure systems

A vial presentation could provide advantages over ampules by reducing glass breakage and simplifying withdrawal. Key requirements include:

• Low-sorption elastomer.
• Minimal tungsten and silicone-related particulate risk.
• Strong container-closure integrity.
• Low extractables and leachables.
• Compatibility with automated pharmacy systems.
• Clear inspection of the dark-colored solution.

A prefilled syringe is technically more demanding because of viscosity, needle force, syringe-material compatibility, and the need to preserve the complex during storage.

Stability-enhanced formulations

A formulation that supports longer room-temperature exposure, reduced sensitivity to agitation, or improved freeze-thaw resistance could reduce distribution losses. The strongest claims would link a defined excipient or process condition to a measurable stability benefit.

Useful targets include:

• Lower aggregate formation.
• Reduced surface adsorption.
• Reduced iron release during storage.
• Reduced particulate generation.
• Better compatibility after dilution into common infusion fluids.

Any stabilizer must be evaluated for its effect on iron availability and complex integrity. A surfactant may reduce surface-induced aggregation but could introduce new parenteral safety and impurity concerns.

Lower-volume dosing

At 50 mg/mL, large replacement doses require multiple milliliters. A higher-concentration product could reduce administration volume, but concentration changes may affect viscosity, osmolality, infusion tolerability, and intramuscular injection feasibility.

A high-concentration product would likely require a new regulatory and clinical package unless it can be convincingly bridged to the reference product.

Premixed combination products

Combining iron dextran with another active ingredient is less attractive. Iron can interact with many drug substances and infusion materials, and combination products create additional regulatory and stability burdens. The more commercially viable approach is a delivery or packaging platform rather than a fixed-dose combination.

How does INFeD compare with other intravenous iron products?

INFeD competes with iron sucrose, ferric carboxymaltose, ferumoxytol, ferric derisomaltose, and other parenteral iron products. Its potential advantages include high iron concentration and the ability to deliver substantial replacement doses. Its principal commercial disadvantage is the boxed warning and established concern regarding serious hypersensitivity reactions associated with iron dextran products.[1]

Product class	Complexing ligand	Typical commercial positioning	Excipient opportunity
INFeD	Dextran	High-dose iron replacement; IV or IM labeling	Safer administration, stability, packaging
Iron sucrose	Sucrose	Broad hospital and outpatient use	Dilution, ready-to-use formats
Ferric carboxymaltose	Carboxymaltose	High-dose IV treatment	Device and infusion convenience
Ferumoxytol	Carbohydrate complex	High-dose infusion with specific labeling	Infusion safety and presentation
Ferric derisomaltose	Derisomaltose	Large-dose replacement	Cost, dosing convenience, supply reliability

Excipient innovation alone is unlikely to overcome a substantial safety or prescribing disadvantage. The commercial proposition must combine formulation execution with lower acquisition cost, easier administration, improved supply, or a credible safety benefit.

What FDA regulatory pathway applies to an INFeD competitor?

A conventional generic strategy would generally use an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the FDA’s product-specific requirements for the complex injectable.

A materially modified iron-dextran formulation may instead require a 505(b)(2) application. This could apply where the product has:

• A different concentration.
• A different route or dosing regimen.
• A new container or delivery device with clinical consequences.
• A new excipient affecting product performance.
• A new indication or administration method.
• A different complex structure or manufacturing process.

A 505(b)(2) strategy can support differentiated claims but usually requires more development than a tightly matched ANDA.

Which companies are positioned to challenge INFeD commercially?

The most credible competitors are established manufacturers of sterile injectables and generic parenteral iron. Relevant capabilities include:

• Aseptic filling.
• Complex injectable characterization.
• Sterile glass and elastomer systems.
• Hospital contracting.
• Pharmacovigilance for hypersensitivity reactions.
• Reliable supply of iron and dextran raw materials.

The strongest entrant is not necessarily the company with the most novel excipient. It is the company that can demonstrate consistent complex quality, maintain low particulate levels, meet FDA manufacturing expectations, and secure hospital purchasing contracts.

What geographic opportunities exist for iron dextran excipients?

The United States offers a defined FDA pathway and a hospital-driven market. Europe and other regulated markets may impose different expectations for complex iron-carbohydrate comparability, pharmacopoeial compliance, excipient acceptability, and naming conventions.

A global excipient strategy should account for:

• USP, Ph. Eur., and other pharmacopoeial requirements.
• Regional limits for elemental impurities.
• Different permitted packaging materials.
• Local injectable excipient precedents.
• Country-specific rules for iron-carbohydrate complexes.
• Variation in hospital preparation practices.
• Cold-chain and room-temperature distribution conditions.

A platform developed solely around a U.S. formulation may require reformulation or additional stability work for other markets.

What revenue exposure is associated with INFeD?

INFeD is not a blockbuster-scale product in the manner of leading branded biologics. Its revenue exposure is concentrated in:

• Hospital and outpatient infusion procurement.
• Shortages or supply interruptions affecting competing iron products.
• Formulary preference.
• Contract pricing.
• Product availability in specific dose sizes.
• Physician and institutional tolerance for iron-dextran hypersensitivity risk.

The commercial value of a differentiated presentation is therefore measured in formulary access, conversion rates, manufacturing margin, and supply reliability. A modest formulation improvement can have value if it lowers administration cost or permits a favorable contract position.

What generic launch scenarios exist for INFeD?

Scenario 1: Matched ANDA

The entrant closely matches the reference composition and presentation. This offers the lowest development risk and the fastest path to interchangeability if FDA requirements are met. The disadvantage is limited differentiation and price pressure.

Scenario 2: Improved packaging

The active complex remains substantially comparable, but the product moves to a vial, prefilled syringe, or pharmacy-ready format. This can support a commercial premium but may require device, stability, and human-factors work.

Scenario 3: 505(b)(2) reformulation

The sponsor claims improved stability, lower administration burden, or a distinct dosing profile. This creates a broader commercial proposition but carries higher clinical and regulatory expense.

Scenario 4: Supply-led entry

The entrant offers a conventional product with dependable supply and aggressive contracting. For an old injectable, this may be the most practical route to market share.

Key Takeaways

• INFeD contains 50 mg/mL elemental iron in an iron-dextran complex.
• The formulation uses a minimal aqueous excipient system, with water for injection and pH adjustment by hydrochloric acid and/or sodium hydroxide identified in FDA labeling.
• Dextran is part of the active iron complex and cannot be treated as a freely interchangeable excipient.
• The best generic strategy is close physicochemical matching, not excipient novelty.
• The strongest differentiated opportunities are ready-to-use presentations, improved container systems, lower particulate burden, extended stability, and administration-cost reduction.
• A new buffer or surfactant alone is unlikely to create durable commercial or patent value.
• Generic development is technically demanding because iron dextran is a complex injectable product.
• An ANDA is the likely route for a close equivalent; a materially modified product may require a 505(b)(2) application.
• Current Orange Book listings, therapeutic-equivalence codes, and patent certifications must control any Paragraph IV or launch analysis.
• Commercial success depends heavily on supply reliability, hospital contracts, administration convenience, and hypersensitivity-risk management.

FAQs

Can sodium chloride be added to an INFeD reformulation?

Sodium chloride could be evaluated as a tonicity agent, but it should not be added solely to make the formulation isotonic. The sponsor must assess its effect on osmolality, iron-complex stability, viscosity, particulate formation, dilution compatibility, and reference-product comparability.

Would a polysorbate improve iron-dextran stability?

A polysorbate might reduce adsorption or surface-induced aggregation in some injectable systems, but it introduces oxidation, peroxide, particulate, and compatibility risks. It would require a strong formulation rationale and extensive stability data.

Is a preservative-free INFeD vial commercially preferable?

Yes, in most hospital settings. A single-dose, preservative-free presentation reduces preservative exposure and simplifies intravenous use. A multidose preserved product would face additional safety, compatibility, and in-use stability requirements.

Can an iron-dextran product claim reduced anaphylaxis risk through excipient selection?

A credible reduced-risk claim would require evidence that the formulation or complex has lower immunologic or complement-related activation. Conventional excipient substitution alone would not establish a clinically meaningful safety advantage.

Does a new iron-dextran excipient composition automatically receive patent protection?

No. Patentability would depend on novelty, non-obviousness, written description, enablement, and a defensible relationship between the composition and a measurable technical result. A routine buffer or tonicity adjustment is unlikely to provide strong protection without unexpected performance.

References

1. U.S. Food and Drug Administration. (n.d.). INFeD: Iron dextran injection, USP prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2013). Guidance for industry: Drug products containing nanomaterials. FDA. https://www.fda.gov/

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/